Physician profile
Shela Gu
NPI 1497287056
$1,469.73
in general payments reported to CMS, 2019-2025
21 companies · $439 in 2025
The $439 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.68 · 2022: $142 · 2023: $494 · 2024: $297 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $223.85 | 2023-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $211.70 | 2022-2025 | Doc Band |
| Sanofi Pasteur INC. | $167.62 | 2021-2023 | |
| Glaxosmithkline, LLC. | $140.32 | 2022-2025 | Bexsero |
| Corium, LLC | $100.68 | 2022-2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $98.77 | 2025 | Jornay Pm |
| Merck Sharp & Dohme LLC | $82.92 | 2023-2025 | Vaxneuvance, Gardasil 9, Enflonsia |
| Ironshore Pharmaceuticals INC. | $72.93 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.85 | 2021-2022 | |
| Seqirus USA INC | $46.87 | 2023-2024 | Flucelvax Quadrivalent, Flucelvax |
| Vertical Pharmaceuticals, LLC | $37.67 | 2023 | Relexxii |
| Verrica Pharmaceuticals INC. | $37.47 | 2024 | Ycanth |
| Acadia Pharmaceuticals INC | $28.74 | 2025 | Daybue |
| Lnhc, INC | $27.94 | 2025 | Zelsuvmi |
| Intrabio INC | $25.10 | 2025 | Aqneursa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $24.87 | 2022 | |
| Cipher Pharmaceuticals US LLC | $23.77 | 2025 | Spinosad, Natroba |
| Kaleo, INC. | $18.76 | 2023 | Auvi-Q |
| Neos Therapeutics, LP | $16.31 | 2024 | Cotempla Xr-Odt |
| Sobi, INC | $13.53 | 2022 | |
| Phadia US INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shela Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.